Lysosomal cysteine cathepsin B participates in numerous diverse cellular processes. In acquiring its activity, the proregion, which blocks the substrate-binding site in the proenzyme, needs to be cleaved off. Here we demonstrate that polyanionic polysaccharides, glycosaminoglycans (GAGs), can accelerate the autocatalytic removal of the propeptide and subsequent activation of cathepsin B. We show that naturally occurring GAGs such as chondroitin sulfates and heparin, as well as the synthetic analog dextran sulfate, accelerate the processing in a concentration-dependent manner. Heparin oligosaccharides down to the size of tetrasaccharides were efficient in accelerating the procathepsin B processing, whereas disaccharides were without effect. Further, the ability of the GAGs to accelerate procathepsin B processing was sensitive to increasing NaCl concentrations, indicating that electrostatic interaction between the GAGs and procathepsin B are operative in the accelerating effect. Also the processing of the catalytic procathepsin B mutant by wild type cathepsin B was enhanced in the presence of GAGs, suggesting that GAGs induce a conformational change in procathepsin B, converting it into a better substrate. Site-directed mutagenesis showed that His 28 , Lys 39 , and Arg 40 , located within the procathepsin B propeptide, have significant roles in the acceleration of procathepsin B activation induced by short GAGs. Because procathepsin B and GAGs often co-localize in vivo, we propose that GAGs may play a physiological role in the activation of procathepsin B.
Zymogen activation is one of the most critical steps in the regulation of protease activity. In general, activation is achieved by a proteolytic removal of parts of the proenzyme, a process that is sometimes accompanied by a conformational rearrangement of the mature enzyme (1) . Cysteine cathepsins, a group of proteases that plays a critical role in intracellular protein turnover in lysosomes and in processes such as antigen processing and presentation, bone remodeling, and proteolytic activation of different proteins including other proteases, are synthesized as inactive preproenzymes (2, 3) . The prepeptide serves as a signal peptide for targeting to the endoplasmic reticulum, where it is removed during the transport, whereas the propeptide facilitates folding of the enzyme, acts as an inhibitor preventing inappropriate proteolytic activity of the zymogen, and is responsible for targeting to endosomes and/or lysosomes (4) . The propeptide, which runs in an extended conformation through the active site cleft, forms an ␣-helical domain on top of the enzyme, which serves to anchor the prodomain to the body of the enzyme (5) . Proteolytic removal of the prodomain, which is required for the activation of cysteine cathepsins, occurs in the acidic milieu of the endosomal/lysosomal system (6, 7) . Endopeptidases, such as cathepsins B, L, S, and K, can be activated autocatalytically or by other proteases such as cathepsin D and pepsin (2, 7, 8) , whereas exopeptidases such as cathepsins X and C require other proteases, including cysteine cathepsins, for their activation (9, 10) .
Glycosaminoglycans (GAGs) 2 are heteropolysaccharides composed of repeating disaccharide units with a high negative charge caused by the presence of multiple carboxyl groups and sulfate substitutions. GAGs and various other polysaccharides, such as dextran sulfate, were previously found to facilitate the autocatalytic processing of various cysteine cathepsins to their mature forms (11) (12) (13) . Moreover, dextran sulfate was demonstrated to enable activation of procathepsin S (13) , and of procongopain from Trypanosoma congolense (14) even at neutral pH. In addition, GAGs have been shown to increase the stability of mature cathepsin B at neutral pH (15) and to modulate the collagenolytic activity of cathepsin K (16) .
Because GAGs are found in the lysosomes, the main site of their recycling (17) , and are prominent components of connective tissues, a location to which cysteine cathepsins are targeted in certain pathologies (18 -22) , it is thereby clear that GAGs have the potential to interact with and regulate the activities of cysteine cathepsins during physiological and pathophysiological conditions. However, the molecular mechanism by which GAGs facilitate cathepsin activation has not yet been elucidated. In this study, cathepsin B, which is often found outside lysosomes or even extracellularly, such as in cancer (reviewed in Ref. 21) , arthritis (18, 20 -22) , and neurodegeneration (19) , was chosen as a model enzyme to address this issue. To clarify the mechanism by which GAGs promote cathepsin activation, the ability of GAGs of different structures and charge densities (chondroitin sulfates A, B, C, and E, hyaluronan, heparan sulfate, and heparin), size of the GAG units (2-mer to 24-mer of heparin), and ionic strength on activation of procathepsin B were studied. In addition, several charged residues in procathepsin B were mutated to elucidate their individual contribution to GAG binding.
EXPERIMENTAL PROCEDURES
Materials-Heparin oligosaccharides (6-, 8-, 10-, 12-, 18-, and 24-mer), heparan sulfate, and pig mucosal heparin were generous gifts from Dorothe Spillmann and Ulf Lindahl (Uppsala University, Uppsala, Sweden). Chondroitin sulfates (A, B, and E) were from Calbiochem. Chondroitin sulfate C and hyaluronan were from Sigma. Heparin-derived disaccharide and tetrasaccharide were purchased from Neoparin (San Leandro, CA). Z-Arg-Arg-AMC was obtained from Bachem (Bubendorf, Switzerland). Dimethyl sulfoxide was from Merck. E-64 was purchased from Peptide Research Institute (Osaka, Japan). Nucleic acid sequencing reagents were from Applied Biosystems (Foster City, CA).
Production and Purification of Procathepsin B-Expression of recombinant human procathepsin B and its mutants in Escherichia coli and their purification have been described previously (23) . Protein concentrations were determined by absorbance measurements using a PerkinElmer Life Sciences -18 spectrophotometer according to Pace et al. (24) . Concentrations of active enzymes were determined by titration with the general cysteine proteinase inhibitor E-64 (25) .
Site-directed Mutagenesis-Site-directed mutagenesis was performed as described previously (26) . The sequence of human preprocathepsin B (27) was used to design the following mutagenic oligonucleotides: 5Ј-GCAGGCCCTCTTTCGCT-CCCCTGTCGGATGAG-3Ј for HisP 7 3 Ala; 5Ј-GGTCAAC-TATGTCAACGCAGCGAATACCACGTG-3Ј for LysP 19 3 Ala,ArgP 20 3 Ala; 5Ј-ACGTGGCAGGCCGGGGCCAACTT-CTACAACGTG-3Ј for HisP 28 3 Ala; 5Ј-GGACATGAGCTA-CTTGGCGAGGCTATGTGGTACCTTC-3Ј for LysP 39 3 Ala; 5Ј-GGACATGAGCTACTTGAAGGCGCTATGTGGTACC-TTC-3Ј for ArgP 40 40 3 Ala quadruple mutant, a sequential mutagenesis using HisP 7 3 Ala and HisP 28 3 Ala mutagenic oligonucleotides and a mutagenic oligonucleotide 5Ј-GGACATGAGCTA-CTTGGCAGCGCTATGTGGTACCTTC-3Ј for introducing LysP 39 3 Ala,ArgP 40 3 Ala mutations was performed.
Kinetic Measurements-Activation rate of procathepsin B was measured as described previously (12) . Briefly, procathepsin B (final concentration, 0.37 M) was processed in 1 ml of the processing buffer (0.1 M sodium acetate, pH 4.5, containing 5 mM cysteine) at 37°C in the absence or presence of 10 l of different GAG solutions. Aliquots of 20 l were withdrawn from the mixture at appropriate times and added to 2.5 ml of substrate solution containing 10 M Z-Arg-Arg-AMC in 0.1 M phosphate buffer, pH 6.0, containing 1 mM EDTA and 0.1% (w/v) polyethyleneglycol 6000 (Serva, Heidelberg, Germany). The final concentration of dimethyl sulfoxide was less than 3%. Fluorescence of the released product was monitored continuously for 60 s in a PerkinElmer Life Sciences LS-50 spectrofluorimeter at excitation and emission wavelengths of 370 and 460 nm, respectively. All of the experiments were performed at least in duplicate.
Proteolytic 
RESULTS

Expression and Characterization of Wild
Type and Procathepsin B Mutants-To study the effect of different GAGs on processing of procathepsin B, recombinant human procathepsin B and various mutants were expressed as inclusion bodies in E. coli, refolded, and purified. The homogeneity of purified recombinant proteins was verified by SDS-PAGE under reducing conditions (data not shown). To determine the active site concentrations of the mutants to standardize the assays, procathepsin B variants of known concentration were first processed for an hour at pH 4.5, which was sufficient for full activation. Next, the mixtures were active site-titrated with E-64, and all of the cathepsin B variants were found to be 33-58% active (not shown).
Dependence of Procathepsin B Activation Rate on GAG Concentration-First, the influence of several naturally occurring GAGs on the rate of procathepsin B activation was investigated. Chondroitin sulfates A, B, C, and E, hyaluronan, heparan sulfate, and heparin were all found to substantially accelerate procathepsin B activation. To quantify the effect, half-times (t1 ⁄ 2 ) of the processing (i.e. time, needed for cathepsin B to achieve 50% final activity) were determined at increasing GAG concentrations (0.1-100 g/ml). With all GAGs, a sigmoid increase in cathepsin B activity with time was observed, indicative of bimolecular processing. None of the GAGs inves-tigated significantly affected the level of final cathepsin B activity at any concentration used (data not shown), indicating that the GAGs only affect the rate of proenzyme processing without influencing the catalytic efficiency of fully processed enzyme. The latter notion is consistent with previous data (12, 13, 28) . As shown in Fig. 1 , increasing GAG concentrations resulted in 7-10-fold reduction of the half-time for completed procathepsin B processing. For most of the GAGs, maximal acceleration was obtained at concentrations as low as 5-20 g/ml. The only exception was hyaluronan, for which maximal effect required 100 g/ml. Further increases in GAG concentrations above those needed for maximal accelerating effect had no additional effect on the activation rate. In a separate experiment, dextran sulfate was shown to be less potent than chondroitin and heparan sulfates (Fig. 1) .
Effect of GAG Size on Processing of Procathepsin B-To further understand the mechanism of the GAG-mediated acceleration of cathepsin B processing, the length of GAGs required for acceleration of the processing rate was studied using heparin-derived oligosaccharides of defined size, ranging from 2 to 24 saccharide units. As shown in Fig. 2 , the addition of 12-24-mer heparin oligosaccharides to the processing mixture accelerated the processing slightly more efficiently than the addition of short oligosaccharides (4 -10-mers). The final rates of Z-Arg-Arg-AMC hydrolysis (by fully processed cathepsin B) were the same regardless of the absence or presence of heparin oligosaccharide, thus arguing against the possibility that the heparin oligosaccharides caused a change in catalytic efficiency of cathepsin B, as opposed to an effect on its rate of activation. A more detailed analysis of the half-times of processing revealed that the heparin oligosaccharide concentration (C 50 ) required for 50% shortening of the half-time of processing from ϳ50 to 25 min, was within the 0.055-0.800 M range (Fig. 2B) . Further increasing the oligosaccharide concentration up to the highest concentration used (1-40 M, depending on the oligosaccharide size) led to a further decrease of half-times of processing to the minimum values (3-10 min). No tendency of deceleration was observed even at the highest oligosaccharide concentrations used. The addition of heparin-derived disaccharides to the processing mixture had only a marginal effect (Fig. 2) , suggesting that tetrasaccharide is the minimal oligosaccharide required for the acceleration effect. 
Glycosaminoglycans Increase Susceptibility of Procathepsin B
for Proteolytic Processing-An important question is whether the stimulating effect of GAGs on procathepsin B processing is explained by direct stimulation of the endopeptidase activity of procathepsin B or whether the stimulating effect is explained by conversion of procathepsin B into a better substrate for cathepsin B by GAGs binding caused by induction of a conformational change. Because previous studies have indicated that GAGs do not affect the endopeptidase activity of cathepsin B toward different protein substrates (15, 28) , we therefore investigated the alternative possibility. For this purpose we generated enzymatically inactive procathepsin B, i.e. a mutant that could not contribute to the processing, by mutating Cys 29 into Ser (12) . When the procathepsin B Cys 29 3 Ser mutant was incubated with mature cathepsin B, time-dependent processing of procathepsin B Cys 29 3 Ser mutant was clearly visible, although residual procathepsin B was still visible even after 18 h of incubation (Fig. 3, left panel) . When either heparin tetrasaccharide or chondroitin sulfate A was added, a striking enhancement of procathepsin B Cys 29 3 Ser mutant processing was apparent, with completed processing already after 3 h of incubation (Fig.  3, middle and right panels) . Together, these results suggest that GAG binding induces a conformational change in procathepsin B, which converts procathepsin B into a better substrate for cathepsin B.
GAGs Bind to Procathepsin B through Charge-Charge Interactions-Because GAGs are known to predominantly interact with their target proteins through electrostatic interactions (15, 29) , it appeared likely that ionic interactions are of major importance for the GAG-facilitated acceleration of procathepsin B processing. To test this hypothesis, the effect of GAGs on the processing rate of procathepsin B was studied in the presence of increasing NaCl concentrations. The accelerating effect of GAGs on the autocatalytic processing markedly decreased with increasing ionic strength and was completely abolished at 0.5 M NaCl (Fig. 4) . In a control experiment, performed in the absence of GAGs, even 1.0 M NaCl had no effect on the processing rate of procathepsin B (not shown), indicating that increased ionic strength interferes with an electrostatic interaction between GAG and procathepsin B, rather than causing direct effects on cathepsin B activity. Moreover, procathepsin B was shown to bind to a HiTrap heparin HP heparinSepharose column and could be eluted with NaCl, further supporting an electrostatic nature of the interaction between procathepsin B and GAGs. 3 
Toward Identification of GAG-binding Site(s)-Having
shown that GAGs accelerate procathepsin B activation via ionic interactions that induce a conformational change in the zymogen, our next aim was to identify the charged residues on the procathepsin B molecule that were involved in the interactions with GAGs. The low affinity of heparin binding to mature cathepsin B (15) suggested that the binding site might be located within the propeptide, which is removed during processing (2) .
There are several positively charged residues in the propeptide, among them HisP 7 the electrostatically favorable environment, were the next candidates for an interaction with GAGs that cause accelerated proenzyme processing, although they do not make any salt bridges with the mature enzyme. To test this hypothesis, HisP 28 3 Ala, LysP 39 3 Ala, and ArgP 40 3 Ala single mutants were generated. In addition, an ArgP 54 3 Asn mutant was prepared to investigate the possibility that ArgP 54 , which is located downstream of the active site in close vicinity of the propeptide cleavage site, could contribute to the interaction.
First, the processing of the various mutants was investigated in the absence of added GAGs. As shown in Fig. 6 , processing of both the double mutant LysP 19 3 Ala,ArgP 20 3 Ala and, in particular, the single ArgP 54 3 Asn mutant was slower than that of the wild type enzyme, suggesting that these residues are not involved in interactions that constrain proenzyme activation. Also the processing of the HisP 28 3 Ala mutant was slower than that of the wild type. In contrast, processing of the LysP 39 3 Ala and ArgP 40 3 Ala, mutants were faster than the processing of wild type procathepsin B (Fig. 6) , suggesting that these charged residues in the interface between the propeptide and main body of enzyme are involved in the enzyme activation process.
In the next step, we investigated the effect of GAGs on the autoprocessing of procathepsin B mutants. Strikingly, the enhancing effect of heparin tetrasaccharides on procathepsin B processing was reduced by over 49% for both the LysP 39 3 Ala and HisP 28 3 Ala mutants (Fig. 6 ), indicating that LysP 39 and HisP 28 have key roles in the GAG-induced acceleration of procathepsin B processing. Also the processing of the ArgP 40 3 Ala mutant was stimulated to a lesser extent by heparin tetrasaccharide than wild type procathepsin B, although the effect was not as pronounced as for the LysP 39 3 Ala and HisP 28 3 Ala mutants. Thus, ArgP 40 also appears to contribute to the effect of GAGs on procathepsin B processing. In contrast, the processing of the LysP 19 3 Ala, ArgP 20 3 Ala, and ArgP 54 3 Asn mutants were stimulated to the same or even higher extent by heparin tetrasaccharide as wild type procathepsin B, indicating that neither of these amino acid residues are involved in the GAG-induced acceleration of procathepsin B processing (Fig. 6 ).
Because the results described above suggest that HisP 28 , LysP 39 , and ArgP 40 all contribute to the effect of short GAGs on procathepsin B processing, we next investigated the effect of mutating them simultaneously, i.e. a mutant where all of these residues, as well as HisP 7 , a neighboring residue (Fig. 5) , were mutated. Strikingly, when assessing the processing rate for the HisP 3 Ala quadruple mutant, the accelerating effect was almost completely abolished (Fig. 6) , clearly suggesting that LysP 39 , ArgP 40 , HisP 28 , and possibly HisP 7 hold key roles in the enhancement of procathepsin B processing induced by short GAGs. However, these effects were not seen when intact chondroitin sulfate A was used instead of the heparin tetrasaccharide. In the latter case, substantial enhancement of procathepsin B processing was induced for all of the procathepsin B mutants.
From the three-dimensional structure of procathepsin B (5, 30, 31), it is evident that the propeptide interacts, in addition to the body of the enzyme, also with the occluding loop. Moreover, His 111 from the occluding loop has been shown to be important for the interaction between heparin and the mature form of cathepsin B (15) . In addition to His 111 , two other positively charged residues are present in the occluding loop, His 110 and Arg 116 , and they form salt bridges with Asp 22 and Asp 224 , respectively, from the main body of the enzyme. Removal of these contacts results in a substantial increase in the endopeptidase activity of cathepsin B (32), indicating that His 110 and Arg 116 are important for regulation of cathepsin B endopeptidase activity. To evaluate the contribution of positively charged residues in the occluding loop to the GAG-induced acceleration of procathepsin B processing, procathepsin variants were generated in which His 110 , His 111 , or Arg 116 were mutated to Ala.
As shown in Fig. 6 , mutating His 111 to Ala dramatically reduced the processing time (ϳ6-fold). Because the processing was accompanied by a substantially higher final activity of the mutant on Z-RR-AMC substrate (ϳ5-fold; not shown), this effect could be attributed predominantly to a substantially increased endopeptidase activity of this variant, in agreement with earlier studies (15, 33) . Further, the processing time was decreased only to a minor extent in the presence of either heparin tetrasaccharide (52%) or chondroitin sulfate (16%), suggesting that His 111 might have a role in the acceleration of procathepsin B processing induced by short GAGs, whereas its role in the acceleration induced by long GAGs is more elusive. However, the values could only be taken as approximate because of the very high processing rates.
Processing of the Arg 116 3 Ala mutant was slower than for wild type enzyme, and the rate of processing was enhanced to a similar extent as for wild type proenzyme. Thus, Arg 116 does not appear to be involved in the GAG-induced acceleration of procathepsin B processing. No autocatalytic processing of the His 110 3 Ala mutant could be detected in the absence of GAGs, suggesting that His 110 might be important for proper folding and/or stability of the enzyme. The addition of GAGs, either heparin tetrasaccharide or chondroitin sulfate A, to the His 110 3 Ala mutant resulted in proenzyme processing at a similar rate as seen for wild type procathepsin B (Fig. 6) . However, because proenzyme processing was not detected in the absence of GAGs, it is obviously not possible to determine whether His 110 contributed to the GAG-induced acceleration of procathepsin B processing.
Conceivably, the lack of activity of the His 110 3 Ala mutant (in the absence of GAGs) could be due to inappropriate folding or autodegradation. However, the ability of the mutant to autoactivate in the presence of GAGs suggested that it is properly folded when GAGs were present. The latter was supported by circular dichroism measurements in the near UV region, which showed that the spectrum of the His 110 3 Ala mutant was very similar to that of the wild type procathepsin B (data not shown). To test the alternative possibility, i.e. whether the lack of activity was a result of autodegradation, the His 110 3 Ala mutant was incubated at pH 4.5 and 37°C for 0, 2, or 18 h, followed by SDS-PAGE analysis. Whereas the wild type protein was properly processed and retained its activity even after 18 h, no activity of the His 110 3 Ala mutant could be detected. Moreover, the protein was gradually processed and completely degraded after 18 h, suggesting that the His 110 3 Ala mutant was slowly autocatalytically degraded (data not shown). These results are in agreement with earlier observations demonstrating that processing of the His 110 3 Ala mutant was extremely slow with a low yield (15, 33) .
DISCUSSION
Autocatalytic activation of cysteine cathepsins is a bimolecular process that results in a proteolytic removal of the prodomain and subsequent activation of the enzyme (12, 13, 34, 35) . Previous studies have shown that the process can be substantially accelerated in the presence of GAGs and other negatively charged polysaccharides (11) (12) (13) (14) . However, a majority of the previous studies were done with dextran sulfate, a nonphysiological polysaccharide as a model compound (12, 13) . Moreover, previous studies have only provided qualitative evidence for the accelerating effect without defining the underlying molecular mechanism. The main goal of this work was therefore to elucidate the molecular mechanism by which GAGs facilitate autocatalytic activation of cysteine cathepsins, by using procathepsin B as a model enzyme.
We show that a number of naturally occurring sulfated GAGs, including heparin, heparan sulfate, and chondroitin sulfates A, B, C, and E were capable of accelerating procathepsin B processing. Interestingly, all of these GAGs were approximately equally effective, findings that have several functional implications. First, the observation that heparan sulfate/heparin and the different chondroitin sulfates were equally effective indicates that the carbohydrate backbone structure is not important for the accelerating effect, given that heparan sulfate and heparin are polymers of [GlcUA/IdoUA-GlcNAc] n units whereas chondroitin sulfates are composed of repeating [GlcUA-GalNAc] n units. Second, the finding that heparin and heparan sulfates are equally effective indicates that the degree of sulfation is not a critical factor for determining the efficacy of promoting procathepsin B processing, considering that heparin has on the average ϳ2.5 sulfate groups/disaccharide, whereas heparan sulfates contain ϳ1 sulfate group/disaccharide unit. This notion is also supported by the equal efficacy of the different chondroitin sulfates, given that chondroitin sulfate E has ϳ2 sulfate groups/disaccharide [GalNAc-4,6-O-sulfate] as compared with chondroitin sulfates A, B, and C, which all have on the average ϳ1 sulfate group/disaccharide unit. Moreover, the location of the sulfate groups did not appear to be critical for the accelerating effect, because chondroitin sulfate A (carrying 4-O-sulfated GalNAc residues) and C (carrying 6-O-sulfated GalNAc residues) were equally effective.
In addition to the sulfated GAGs, the nonsulfated GAG hyaluronan was tested for efficacy in accelerating procathepsin B processing. It was found that also hyaluronan was capable of promoting proenzyme processing, although its efficacy was lower than that of the sulfated GAGs. This indicates that sulfation is important for the accelerating effect, although, as discussed above, the level of sulfation is not critical. However, because hyaluronan was able to promote procathepsin B to some extent, it is clear that sulfation is not an absolute requirement. The mechanism by which hyaluronan accelerates procathepsin B processing is intriguing. Because our results strongly indicate that electrostatic interactions are important for the effect (Fig. 4) , it is likely that hyaluronan promotes procathepsin B processing by engaging in electrostatic binding with the proenzyme. Further, because the only charged component of hyaluronan is the carboxyl groups of the GlcUA moiety of the repeating disaccharide units, our findings indicate an important role of carboxyl groups in the acceleration effect. In support of such a notion, it was found that dextran sulfate, a synthetic polysaccharide of high sulfate content (similar or even higher than heparin) but devoid of carboxyl groups, was less effective than all of the sulfated natural GAGs in accelerating procathepsin B activation (Fig. 1) .
Together, these findings point to a mode of interaction with GAGs that differs substantially from most known interactions between proteins and GAGs. In most cases in which the interaction between a protein and a GAG has been characterized in detail, the efficiency of interaction is highly dependent on the level of sulfation of the GAG, with the highly sulfated polysaccharides heparin and dextran sulfate usually being far more effective than less sulfated GAGs such as heparan sulfate and chondroitin sulfate A and C (36 -39) . Moreover, in many previously published studies, hyaluronan has been shown to be virtually completely unable to substitute for highly sulfated GAGs in the interaction in question (36, 38) . Another unusual feature of the interaction between procathepsin B and GAGs is that the minimal oligosaccharide required for interaction is unusually small. In most other cases, binding does not occur to oligosaccharides smaller than octasaccharides (37, 38, 40, 41) , whereas the interaction with procathepsin B requires only a tetrasaccharide for optimal interaction. Thus, the interaction between GAGs and procathepsin B displays a number of unique features.
In general, there are two known major mechanisms by which GAGs facilitate protein-protein interactions. These can be best exemplified by the heparin acceleration of antithrombin interaction with thrombin and Factor Xa, respectively. Binding of heparin to antithrombin is known to induce a conformational change in the latter. Whereas this is completely sufficient for full acceleration of antithrombin interaction with Factor Xa, it has only a minor effect on the antithrombin-thrombin interaction. Instead, long GAG chains are required for complete acceleration (ϳ1000-fold), which could be explained by a surface approximation or "bridging" effect, where long GAGs promote an initial encounter between antithrombin and thrombin after diffusing along the polysaccharide molecule. However, increasing the GAG concentration leads to numerous GAG molecules competing for individual antithrombin and thrombin molecules, resulting in antithrombin and thrombin molecules bound to different GAG molecules and thereby deceleration of the process (reviewed in Ref. 29 ). In our model, 30 -100-fold increases in the GAG concentration ( Figs. 1 and 2 ) did not diminish the acceleration effect, suggesting that GAG molecules do not compete with each other even at a molar excess of GAGs. Furthermore, even small GAGs such as tetrasaccharides had a pronounced effect on the activation rate of procathepsin B, arguing against the bridging effect. Together, the data thus point to the model in which GAGs induce a conformational change in procathepsin B and where the putative conformational change is sufficient for complete acceleration.
The low concentration of heparin derivatives required for 50% maximal acceleration (0.055-0.800 M) suggests a relatively high affinity binding, although the affinity is probably lower than the affinity of heparin for antithrombin (K d Х 20 nM; Ref. 42) . Interestingly, heparin has been shown to bind mature cathepsin B with a low affinity (K d ϭ ϳ33 M; Ref. 15) , thus introducing the possibility that the affinity of GAGs for the mature enzyme is considerably lower than their affinity for the proenzyme. This is further supported by the finding that the catalytic procathepsin B Cys 29 3 Ser mutant can be processed by the wild type enzyme substantially faster in the presence of GAGs, whereas GAGs had no effect on azocasein or gelatin degradation by wild type cathepsin B (15, 28) . Moreover, the concentration of GAGs is considerably lower than the concentration of procathepsin B used (0.37 M), indicating that the GAG molecules exhibit their full potential already at catalytic concentrations. Together, these findings suggest a mechanism in which the GAGs act in a catalytic fashion by first binding to the proenzyme, thereby promoting its cleavage, followed by the release of the GAG after proenzyme cleavage and binding to a new proenzyme molecule.
In agreement with essentially all other known interactions between GAGs and proteins (reviewed in Ref. 29; Refs. 15, 43, and 44) , ionic interactions between GAGs and procathepsin B were found to be crucial (Fig. 4 and Refs. 5 and 32). Further, our results are compatible with a scenario where GAG binding induces a conformational change in the proenzyme, converting it into a better substrate. From the crystal structure of procathepsin B, it is evident that the propeptide, which runs in an extended conformation across the active site cleft, is kept in its position within the active site cleft through hydrophobic and hydrophilic interactions with both the main body of the enzyme and the occluding loop, lifting the latter above the enzyme surface ( Fig. 5 and Ref. 5) . Furthermore, the only differences between the structures of procathepsin B and mature cathepsin B were the presence of the propeptide in the zymogen and consequently perturbed position of the occluding loop, whereas the structure of the main body of the enzyme was essentially the same (5, 30, 31, 45) . However, the structure of mature cathepsin B was found to be affected by heparin binding (15) , although the binding affinity of GAGs for mature cathepsin B is presumably considerably lower from that for the zymogen. It can be therefore suggested that GAG binding to charged residues on procathepsin B induces conformational change(s) within the propeptide, within the linker region between the propeptide and the main body of the enzyme, where the final processing cleavage occurs, and/or within the main body of the enzyme. Mutagenesis studies identified HisP 28 , LysP
39
, and ArgP 40 in the propeptide as key residues in mediating the effect of short GAGs on procathepsin B processing, whereas the binding sites for long GAGs were not identified (Fig. 6 ). Although we cannot with certainty explain the differential effects of the short and long GAGs, a plausible explanation is that short GAGs can enter the active site cleft, where they bind to HisP 28 , LysP 39 , and ArgP 40 , thereby pushing the propeptide away from the active site cleft because of steric clashes with the active site cleft residues. This could result in a higher susceptibility of the zymogen for cleavage. In turn, this may result in increased endopeptidase activity of the zymogen. In contrast, long GAGs, such as chondroitin sulfate A, may be unable to enter the active site cleft and may thus primarily interact with charged residues at the main body surface of the procathepsin B molecule. The ability of the long GAGs to interact with residues at the surface of the main body of procathepsin B could be facilitated through multivalent interactions of the long GAGs with positively charged residues, separated by some distance on the molecular surface, whereas conceivably, short GAGs cannot be engaged in such multivalent interactions. In agreement with such a scenario, a positively charged patch including Lys 18 (5, 31) . Possibly, such interactions cause conformational changes that enhance the rate of autocatalytic processing in a similar fashion as short GAGs. This is also in agreement with previous data on procathepsin B processing, where propeptide removal from the active site cleft was suggested to be an important early step in the processing (12, 33) . Although heparin was found to bind to His 111 in the occluding loop in mature cathepsin B (15), we could not confirm that this binding also affects the procathepsin B processing rate. However, mutating His 111 to Ala enhanced the endopeptidase activity of the processed enzyme and increased the flexibility of the propeptide, thereby making it not a very suitable model. A similar problem applies to the His 110 3 Ala mutant, which, in addition to increased endopeptidase activity, suffers from folding problems and decreased sta-bility, in agreement with earlier data (15, 33) . However, we cannot exclude the possibility that long GAGs also interfere with the propeptide-occluding loop interaction.
Based on the data presented here, we may suggest the following mechanism by which GAGs accelerate the processing of procathepsin B (Fig. 7) . In the first step GAGs bind to procathepsin B, thereby inducing a conformational change, which converts the procathepsin B molecule into a better substrate. This enables easier access of the procathepsin B-GAG complex into the active site cleft of another procathepsin B molecule, preferably also in complex with a GAG molecule. In the next step the prodomain is removed by intermolecular proteolytic cleavage(s). Following propeptide dissociation, the bound GAG probably dissociates and is thus free to bind to another procathepsin B molecule. Finally, the newly generated mature cathepsin B molecules enter the cycle, leading to an exponential increase in the processing rate until the activation is completed. A similar, although because of the lack of occluding loop less complicated, mechanism can probably explain the interaction between GAGs and other cysteine cathepsin zymogens, such as cathepsins L and S, where autocatalytic processing was also found to be enhanced by GAGs (11, 13, 34) .
An important question relates to the possible physiological relevance of these findings. Obviously, a biological relevance for an effect of GAGs on procathepsin B processing requires that GAGs of suitable structure co-localize with procathepsin B in vivo. Because lysosomes constitute the cellular site for GAG turnover (17) , GAG and procathepsin B co-localization is likely to occur in vivo. Moreover, because our data indicate that all classes of natural GAGs can promote proenzyme processing, it is likely that procathepsin B will co-localize with a suitable GAG in most cell types, considering that GAG synthesis is a general feature of many cell types, although the class of GAG synthesized varies substantially among different cell types. In further support for a biological significance of these findings is that also small GAG fragments, which could arise from a partial GAG degradation within the lysosome, are effective in promoting procathepsin B processing. An interesting venue for future research will thus be to determine whether the processing of procathepsin B or other cysteine procathepsins is defective in cells lacking individual GAGs. Because GAGs are also important components of extracellular matrix, this could have important consequences for extracellular activities of cathepsins, such as those in cancer and arthritis, where cathepsins have been found to play important roles (3, 21, 46) .
